Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Receivables (2020 - 2022)

4D Molecular Therapeutics (FDMT) has disclosed Change in Receivables for 3 consecutive years, with -$47000.0 as the latest value for Q1 2022.

  • Quarterly Change in Receivables rose 90.98% to -$47000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was -$47000.0 through Dec 2022, up 96.73% year-over-year, with the annual reading at -$47000.0 for FY2022, 96.73% up from the prior year.
  • Change in Receivables for Q1 2022 was -$47000.0 at 4D Molecular Therapeutics, up from -$744000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $590000.0 in Q4 2020, with the low at -$744000.0 in Q4 2021.
  • Average Change in Receivables over 3 years is -$108666.7, with a median of -$99000.0 recorded in 2020.
  • Peak annual rise in Change in Receivables hit 267.55% in 2021, while the deepest fall reached 426.26% in 2021.
  • Over 3 years, Change in Receivables stood at $590000.0 in 2020, then plummeted by 226.1% to -$744000.0 in 2021, then soared by 93.68% to -$47000.0 in 2022.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$47000.0, -$744000.0, and -$427000.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.